- Synaptogenix Inc (NASDAQ: SNPX) has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer’s disease (AD).
- To date, the Company has dosed 58 of its target 100 patients.
- Additionally, the independent Data Safety Monitoring Board (DSMB) confirmed that 40 advanced AD patients had been dosed with Bryostatin without any significant safety issues.
- Price Action: SNOX shares are up 0.57% at $7.05 during the market session on the last check Wednesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.